Effects of Montelukast on free radical production in whole blood and isolated human polymorphonuclear neutrophils (PMNs) in asthmatic children

Saudi Pharmaceutical Journal

Volumn 19, Issue 4, 2011, Pages 215-220

  Al Saadi, Muslim M ^a   Meo, Sultan Ayoub ^a   Mustafa, Ali ^b   Shafi, Ahmed ^a   Tuwajri, Ali S Al ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Antioxidant; Bronchial asthma; Free radicals production; Montelukast

Indexed keywords

MONTELUKAST; REACTIVE OXYGEN METABOLITE;

ADOLESCENT; ANTIOXIDANT ACTIVITY; ARTICLE; ASTHMA; BLOOD; CELL ISOLATION; CHEMOLUMINESCENCE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NEUTROPHIL; PRESCHOOL CHILD; SCHOOL CHILD;

EID: 80052920841     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2011.06.002     Document Type: Article

References (24)

1. Al-Saadi M.M. The clinical utility of montelukast in paediatric respiratory diseases. Pak. J. Med. Sci. 2007, 23(5):962-969.
2. Al-Zamil, Hana A., Ai-Twaijiri, Ali S., Al-Mobeireek., Abdulla F., Mustafa, Ali A. 2005. Effects of zafirlukast on the function of human polymorphonuclear neutrophil leukocytes in asthmatic patients: a prospective, controlled, in vitro study. Curr. Ther. Res. 66(4), 279-293.
3. Anderson R., Theron A.J., Gravett C.M., Steel H.C., Tintinger G.R., Feldman C. Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism. Br. J. Pharmacol. 2009, 156(1):105-115.
4. Anonymous. 2004. Drug Review. Asthma. Montelukast, drugs in context. Part E. Respir. Med. Infect. 1, 1-40.
5. Biber N., Toklu H.Z., Solakoglu S., Gultomruk M., Hakan T., Berkman Z., Dulger F.G. Cysteinyl-leukotriene receptor antagonist montelukast decreases blood-brain barrier permeability but does not prevent oedema formation in traumatic brain injury. Brain Inj. 2009, 23(6):577-584.
6. Bisgaard H., Zielen S., Garcia-Garcia M.L., et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am. J. Resp. Crit. Care Med. 2005, 171:315-322.
7. Bisgaard H. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am. J. Respir. Crit. Care Med. 2003, 167:379-383. Study Group on Montelukast and Respiratory Syncytial Virus.
8. Bousquet J., Demoly P., Humbert M. Montelukast in guidelines and beyond. Adv. Ther. 2009, 26(6):575-587.
9. Cantrell F.L., Farson-Collier M. The benign clinical course following a large pediatric montelukast ingestion. J. Toxicol. Clin. Toxicol. 2004, 42(3):333-334.
10. Currie G.P., Srivastava P., Dempsey O.J., Lee D.K.C. Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists. Q. J. Med. 2005, 98:171-182.
11. Della Bianca, Grzeskowiak M., Cassatella M.A., Zeni L., Rossi F. Phorbol 12-myristate 13-acetate potentiates the respiratory burst while inhibits phosphoinositide hydrolysis and calcium mobilization by formyl-methionyl-leucyl-phenylalanine in human neutrophils. Biochem. Biophys. Res. Commun. 1986, 135(2):556-565.
12. Diamant Z., van der Molen T. Treating asthma: is there a place for leukotriene receptor antagonists?. Respir. Med. 2005, 99:655-662.
13. Harmanci K. Montelukast: its role in the treatment of childhood asthma. Ther. Clin. Risk Manag. 2007, 3(5):885-892.
14. Henderson W.R., Chiang G.K., Tien Y.T., Chi E.Y. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am. J. Respir. Crit. Care Med. 2006, 173:718-728.
15. Muz M.H., Deveci F., Bulut Y., Illhan N., Yekeler H., Turgut T. The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model. Exp. Mol. Med. 2006, 38:109-118.
16. Nagarajan S., Venkiteswaran K., Anderson M., Sayed U., Zhu C., Selvaraj P. Cell-specific, activation-dependent regulation of Neutrophils CD32A ligand-binding functions. Blood 2000, 95(3):1069-1077.
17. Noiri E., Yokomizo T., Nakao A., Izumi T., Fujita T., Kimura S., Shimizu T. An in ivo approach showing the chemotactic activity of leukotriene B(4) in acute renal ischemic-reperfusion injury. Proc. Natl. Acad. Sci. 2000, 97:823-828.
18. Peters-Golden M., Henderson W.R. Leukotrienes. N. Engl. J. Med. 2007, 357:1841-1854.
19. Raulf, Konig Modulation of leukotriene release from human polymorphonuclear leucocytes by PMA and arachidonic acid. Immunology 1988, 64:51-59.
20. Riccioni G., Bucciarelli T., Mancini B., Di Ilio C., D'Orazio N. Antileukotriene drugs: clinical application, effectiveness and safety. Curr. Med. Chem. 2007, 14:1966-1977.
21. Sener G., Sehirli O., Velioglu-Ogunc A., Cetinel S., Gedik N., Caner M., Sakarcan A., Yegen B.C. Montelukast protects against renal ischemia/reperfusion injury in rats. Pharmacol. Res. 2006, 54:65-71.
22. Smith M.B.H. Is montelukast effective and well tolerated in the management of asthma in young children? Part B: Clinical commentary. Paediatr. Child Health 2007, 12(4):309-310.
23. Tugtepe H., Sener G., Cetinel S., Velioĝlu-Oĝünç A., Yeĝen B.C. Oxidative renal damage in pyelonephritic rats is ameliorated by montelukast, a selective leukotriene CysLT1 receptor antagonist. Eur. J. Pharmacol. 2007, 557(1):69-75.
24. Van Adelsberg, J., Philip, G., Pedinoff, A.J., et al. Montelukast Fall Rhinitis Study Group. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 58, 1268-1276.